Biotech News

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics (ALGS)Aligos TherapeuticsPartnership

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for

Related news

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

ALGSAligos Therapeutics2026-10-05 20:05 EST

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

RYTMRhythm Pharmaceuticals2026-11-03 02:59 EST

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

SENSSenseonics2026-09-14 11:00 EST

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

MLYSMineralys Therapeutics2026-10-22 22:40 EST

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

VKTXViking Therapeutics2026-10-21 20:05 EST

Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026

MLYSMineralys Therapeutics2026-10-02 20:30 EST

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

MNKDMannKind2026-07-24 10:30 EST

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

Stock data

Close
1.25 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States